Article in Arteriosclerosis, thrombosis, and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
31 authors.
Bassim El-Sabawi *Vanderbilt Translational and Clinical Cardiovascular Research Center, Cadiovacsular Medicine Division, Vanderbilt University School of Medicine, Nashville, TN (B.E.-S., A.S.P., K.A., E.F.-E., Q.S.W., J.G.T., J.J.C., R.V.S.).ORCID 0000-0001-5252-4293
Xiaoning Huang *Division of Cardiology (X.H., S.S.K.), Northwestern University Feinberg School of Medicine, Chicago, IL.ORCID 0000-0001-5813-5993
Phillip Lin *Division of Genetic Medicine, Department of Medicine (P.L., M.B., N.K., B.L.A.P., J.M.L., J.B., E.R.G.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0009-0003-6988-0237
Mohammad Yaser Anwar *Department of Epidemiology, School of Public Health, The University of Texas Health Science Center at Houston (M.Y.A., K.E.N.).ORCID 0000-0002-2349-8214
Michael Betti *Division of Genetic Medicine, Department of Medicine (P.L., M.B., N.K., B.L.A.P., J.M.L., J.B., E.R.G.), Vanderbilt University Medical Center, Nashville, TN.
Namju KimDivision of Genetic Medicine, Department of Medicine (P.L., M.B., N.K., B.L.A.P., J.M.L., J.B., E.R.G.), Vanderbilt University Medical Center, Nashville, TN.
Andrew S PerryVanderbilt Translational and Clinical Cardiovascular Research Center, Cadiovacsular Medicine Division, Vanderbilt University School of Medicine, Nashville, TN (B.E.-S., A.S.P., K.A., E.F.-E., Q.S.W., J.G.T., J.J.C., R.V.S.).ORCID 0000-0003-3342-6158
B Lakshitha A PereraDivision of Genetic Medicine, Department of Medicine (P.L., M.B., N.K., B.L.A.P., J.M.L., J.B., E.R.G.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-3015-3529
Priya GajjarCardiovascular Medicine Section, Department of Medicine, Boston University School of Medicine, MA (P.G., D.L.-J., M.N.).ORCID 0009-0002-2693-1578
Laura A ColangeloDepartment of Preventive Medicine (L.A.C.), Northwestern University Feinberg School of Medicine, Chicago, IL.ORCID 0000-0001-9322-705X
Kaushik AmancherlaVanderbilt Translational and Clinical Cardiovascular Research Center, Cadiovacsular Medicine Division, Vanderbilt University School of Medicine, Nashville, TN (B.E.-S., A.S.P., K.A., E.F.-E., Q.S.W., J.G.T., J.J.C., R.V.S.).ORCID 0000-0003-3379-5834
Quanhu ShengDepartment of Biostatistics (Q.S., S.Z., L.K.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0001-8951-9295
Shilin ZhaoDepartment of Biostatistics (Q.S., S.Z., L.K.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-3921-3965
Lindsay K StolzeDepartment of Biostatistics (Q.S., S.Z., L.K.S.), Vanderbilt University Medical Center, Nashville, TN.
Eric Farber-EgerVanderbilt Translational and Clinical Cardiovascular Research Center, Cadiovacsular Medicine Division, Vanderbilt University School of Medicine, Nashville, TN (B.E.-S., A.S.P., K.A., E.F.-E., Q.S.W., J.G.T., J.J.C., R.V.S.).ORCID 0000-0003-0281-3796
Joshua M LandmanDivision of Genetic Medicine, Department of Medicine (P.L., M.B., N.K., B.L.A.P., J.M.L., J.B., E.R.G.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2431-6053
Patricia E MillerDepartment of Biostatistics, Boston University School of Public Health, Boston, MA (P.E.M.).ORCID 0000-0002-0141-717X
Gabrielle Y LiuDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California Davis, Sacramento (G.Y.L.).ORCID 0000-0003-2049-4231
Suman DasDivision of Infectious Diseases, Department of Medicine (Suman Das), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2496-9724
Quinn S WellsVanderbilt Translational and Clinical Cardiovascular Research Center, Cadiovacsular Medicine Division, Vanderbilt University School of Medicine, Nashville, TN (B.E.-S., A.S.P., K.A., E.F.-E., Q.S.W., J.G.T., J.J.C., R.V.S.).ORCID 0000-0003-3899-0313
James G TerryVanderbilt Translational and Clinical Cardiovascular Research Center, Cadiovacsular Medicine Division, Vanderbilt University School of Medicine, Nashville, TN (B.E.-S., A.S.P., K.A., E.F.-E., Q.S.W., J.G.T., J.J.C., R.V.S.).ORCID 0000-0001-6659-3441
Donald Lloyd-JonesCardiovascular Medicine Section, Department of Medicine, Boston University School of Medicine, MA (P.G., D.L.-J., M.N.).ORCID 0000-0003-0847-6110
Saumya DasCardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Boston (Saumya Das).ORCID 0000-0002-4521-4606
Sadiya S KhanDivision of Cardiology (X.H., S.S.K.), Northwestern University Feinberg School of Medicine, Chicago, IL.ORCID 0000-0003-0643-1859
Kari E NorthDepartment of Epidemiology, School of Public Health, The University of Texas Health Science Center at Houston (M.Y.A., K.E.N.).ORCID 0000-0002-8903-0366
Jennifer BelowDivision of Genetic Medicine, Department of Medicine (P.L., M.B., N.K., B.L.A.P., J.M.L., J.B., E.R.G.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-1346-1872
Matthew NayorCardiovascular Medicine Section, Department of Medicine, Boston University School of Medicine, MA (P.G., D.L.-J., M.N.).ORCID 0000-0002-6993-9396
Ravi KalhanDivision of Pulmonary and Critical Care Medicine, Department of Preventive Medicine (R.K.), Northwestern University Feinberg School of Medicine, Chicago, IL.
John Jeffrey Carr *Vanderbilt Translational and Clinical Cardiovascular Research Center, Cadiovacsular Medicine Division, Vanderbilt University School of Medicine, Nashville, TN (B.E.-S., A.S.P., K.A., E.F.-E., Q.S.W., J.G.T., J.J.C., R.V.S.).ORCID 0000-0002-4398-8237
Eric R Gamazon *Vanderbilt Diabetes Center, Vanderbilt University Medical Center, Nashville, TN (E.R.G., R.V.S.).ORCID 0000-0003-4204-8734
Ravi V Shah *Vanderbilt Translational and Clinical Cardiovascular Research Center, Cadiovacsular Medicine Division, Vanderbilt University School of Medicine, Nashville, TN (B.E.-S., A.S.P., K.A., E.F.-E., Q.S.W., J.G.T., J.J.C., R.V.S.).ORCID 0000-0002-4471-7156
Funding
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Marcela Brissova · 2012 to 2026
$29.3M
Transitions from Impaired Respiratory Health to Lung DiseaseR01HL122477 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI RAVI KALHAN · 2014 to 2026
$17.3M
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - COORDINATING CENTER (CC)75N92023D00002 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LI, JING · 2023 to 2025
$6.8M
Longitudinal Changes in Pericardial Adiposity and Subclinical AtherosclerosisR01HL098445 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CARR, JOHN JEFFREY · 2010 to 2013
$4.6M
VGM: Vanderbilt Genomic Medicine Training ProgramT32HG008341 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Nancy J Cox, Joseph F. Peterson · 2016 to 2026
$2.8M
Improving disease subtyping and physiological characterization of adult-onset diabetes in electronic health recordsU01DK140952 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Eric R Gamazon, Maggie Ng · 2024 to 2026
$2.3M
Functional Genomics: A Phenome-wide SurveyR35HG010718 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GAMAZON, ERIC R · 2019 to 2023
$2.2M
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - OAKLAND FIELD CENTER75N92023D00003 · NHLBI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BHATT, ANKEET S. · 2023 to 2025
$2.2M
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - BIRMINGHAM FIELD CENTER75N92023D00005 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEWIS, CORA · 2023 to 2025
$2.2M
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - CHICAGO FIELD CENTERDIVERSITY SUPPLEMENT FOR MORGANN WEST75N92023D00004 · NHLBI · NORTHWESTERN UNIVERSITY · PI CARNETHON, MERCEDES · 2023 to 2025
$2.1M
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - UNIVERSITY OF MINNESOTA FIELD CENTER.75N92023D00006 · NHLBI · UNIVERSITY OF MINNESOTA · PI SCHREINER, PAMELA J · 2023 to 2025
$1.7M
Advancing Multi-Omics and Electronic Health Records Computational MethodologiesR01HG011138 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GAMAZON, ERIC R · 2020 to 2024
backgroundJoint use of multiple molecular layers can be useful to prioritize targets for mechanistic studies. Application of this approach to coronary disease in large populations is an emerging field.
methodsWe used reported circulating proteomic data (Somascan aptamer-based) from ≈3000 individuals in the CARDIA study (Coronary Artery Risk Development in Young Adults), measuring association with prevalent and 10-year incident coronary artery calcium (CAC) score. We used a multiparametric approach to prioritize circulating protein-CAC associations via genomics of circulating protein levels and coronary artery transcription.
resultsProteins linked to prevalent/incident CAC in CARDIA implicated pathogenic mechanisms of vascular disease, including fibrosis and inflammation (GDF-15 [growth/differentiation factor 15], CDCP1 [CUB domain-containing protein 1], GSN [gelsolin], THBS2 [thrombospondin-2], chemokines, RNAS6 [ribonuclease K6]), oxidative lipid metabolism (CILP2; cartilage intermediate layer protein 2), extracellular matrix remodeling and signaling (MMPs [matrix metalloproteinases], TIMP-1 [tissue inhibitor of metalloproteinases 1], integrins), calcification (Notch 1, ARHGAP36 [Rho GTPase-activating protein 36]), and metabolism (GIP [gastric inhibitory polypeptide]), as well as new proteins not previously reported. Using proteome-wide association study genetic approaches, several targets with nominal evidence in CAC proteomics were associated with atherosclerosis or myocardial infarction in over 300K individuals, including PCSK9 (proprotein convertase subtilisin/kexin type 9) and APOC1. Finally, the coronary artery-specific transcriptome-wide association study of CAC yielded genes with previously implicated mechanistic roles in vascular homeostasis, inflammation, and metabolism, as well as genes without previously described function in CAC. Overlap across CAC proteomics and transcriptome-wide association study highlighted genes involved in vascular inflammation (S100A9), cardiac development (HES1 [transcription factor HES-1]), vessel wall structure (SPARCL1 [SPARC-like protein 1]), and vascular dysfunction or plaque (NOTCH3 [neurogenic locus notch homolog protein 3], TNFSF12 [tumor necrosis factor ligand superfamily member 12], S100A12 [protein S100-A12]).
conclusionsThese results report population-level multiomics in human coronary calcification, presenting a method to identify disease-relevant targets through integration of human genetic approaches with multiomics.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.